Ccl19-KO Mouse
一般名
Ccl19-KO
製品ID
S-KO-19837
背景情報
C57BL/6JCya
系統ID
KOCMP-24047-Ccl19-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Ccl19-KO Mouse(カタログ番号S-KO-19837)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Ccl19-KO
系統ID
KOCMP-24047-Ccl19-B6J-VA
遺伝子名
製品ID
S-KO-19837
遺伝子別名
ELC, CKb11, MIP3B, Gm2023, Scya19, exodus-3
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 4
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000102957
NCBIトランスクリプトID
NM_011888
ターゲット領域
Exon 2~4
有効領域の大きさ
~5.3 kb
遺伝子研究の概要
Ccl19, also known as Chemokine (C-C motif) ligand 19, is a homeostatic chemokine abundantly expressed in the thymus and lymph nodes. It primarily regulates immune cell trafficking and is involved in various biological processes such as T cell activation, immune tolerance, and inflammatory responses. It acts through interaction with its cognate receptor CCR7, and the CCL19-CCR7 axis plays a crucial role in the onset of adaptive immunity, with its signaling pathways influencing viral pathogenesis, immune surveillance, and homeostasis [5].
In cancer research, Ccl19 seems to have a dual-edged role. Ccl19-producing fibroblasts promote the formation of tertiary lymphoid structures (TLSs) in colorectal cancer liver metastasis, enhancing the anti-tumor IgG response. CCL19 treatment also promotes TLS neogenesis and prevents tumor growth in mice [1]. In chimeric antigen receptor (CAR)-T cell therapy for solid tumors, engineering CAR-T cells to secrete CCL19 enhances their expansion, migration, and tumor-suppressing abilities. For example, in hepatocellular carcinoma and pancreatic carcinoma xenografts, 7×19 CAR-T cells (secreting IL-7 and CCL19) show superior tumor suppression compared to conventional CAR-T cells [2,3]. In triple-negative breast cancer, CCL19-expressing dendritic cells are associated with favorable responses to anti-PD-(L)1 immunotherapy, and Ccl19 gene ablation dampens CCR7+CD8+ T cells and tumor elimination in response to anti-PD-1 [4].
In allergic airway disease, Ccl19-deficient mice have less allergic airway inflammation, reduced airway hyper-responsiveness, and less IL-4 and IL-13 production, indicating that CCL19 promotes type 2 T-cell differentiation and allergic airway inflammation [6]. In a mouse model of chronic hepatitis B, CCL19 overexpression leads to rapid clearance of intrahepatic HBV through increased intrahepatic CD8+ T-cell proportion and other immune-related mechanisms [7].
In conclusion, Ccl19 is a key regulator in immune-related processes. Model-based research, especially using gene-knockout mouse models in various disease areas such as cancer, allergic airway disease, and viral infection, has revealed its diverse functions. In cancer, it can either promote anti-tumor immune responses or act as a tumor-supportive factor, while in allergic airway disease it contributes to inflammation, and in HBV infection it aids in virus clearance. These findings provide valuable insights into potential therapeutic strategies targeting Ccl19 in different diseases.
References:
1. Zhang, Yifan, Liu, Guangjian, Zeng, Qianwen, Chen, Zhihang, Kuang, Ming. . CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. In Cancer cell, 42, 1370-1385.e9. doi:10.1016/j.ccell.2024.07.006. https://pubmed.ncbi.nlm.nih.gov/39137726/
2. Pang, Nengzhi, Shi, Jingxuan, Qin, Le, Li, Peng, Zhang, Zhenfeng. 2021. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin. In Journal of hematology & oncology, 14, 118. doi:10.1186/s13045-021-01128-9. https://pubmed.ncbi.nlm.nih.gov/34325726/
3. Lu, Li-Li, Xiao, Shu-Xiu, Lin, Zhi-Yuan, Lu, Bin, Wu, Wei-Zhong. 2023. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy. In Cell biology and toxicology, 39, 3101-3119. doi:10.1007/s10565-023-09821-w. https://pubmed.ncbi.nlm.nih.gov/37853185/
4. Wu, Song-Yang, Zhang, Si-Wei, Ma, Ding, Shao, Zhi-Ming, Jiang, Yi-Zhou. 2023. CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer. In Med (New York, N.Y.), 4, 373-393.e8. doi:10.1016/j.medj.2023.04.008. https://pubmed.ncbi.nlm.nih.gov/37201522/
5. Yan, Yan, Chen, Renfang, Wang, Xu, Lu, Mengji, Hu, Qinxue. 2019. CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention. In Frontiers in cell and developmental biology, 7, 212. doi:10.3389/fcell.2019.00212. https://pubmed.ncbi.nlm.nih.gov/31632965/
6. Nakano, Keiko, Whitehead, Gregory S, Lyons-Cohen, Miranda R, Cook, Donald N, Nakano, Hideki. 2023. Chemokine CCL19 promotes type 2 T-cell differentiation and allergic airway inflammation. In The Journal of allergy and clinical immunology, 153, 487-502.e9. doi:10.1016/j.jaci.2023.10.024. https://pubmed.ncbi.nlm.nih.gov/37956733/
7. Yan, Yan, Zhao, Wei, Liu, Wei, Xun, Jingna, Davgadorj, Chantsalmaa. 2021. CCL19 enhances CD8+ T-cell responses and accelerates HBV clearance. In Journal of gastroenterology, 56, 769-785. doi:10.1007/s00535-021-01799-8. https://pubmed.ncbi.nlm.nih.gov/34218330/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
